



Docket No.: 03818/0204416-US0  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Mladen Mercep et al.

Application No.: 10/595,939

Confirmation No.: 9274

Filed: May 19, 2006

Art Unit: N/A

For: 1-AZA-2-OXA-DIBENZO[E,H]AZULENES  
AND THEIR USE FOR THE TREATMENT  
OF CENTRAL NERVOUS SYSTEM  
DISEASES AND DISORDERS

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is submitted in accordance with 37 C.F.R. 1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

1. This IDS should be considered, in accordance with 37 C.F.R. 1.97, as it is filed:  
(Check one of the boxes A-D)

- ☐ A. within three months of the filing date of the above-identified national application or within three months of the entry into the national stage of the above identified national application
- ☒ B. before the mailing date of a first office action on the merits, or a first office action after filing a request for continued examination.
- ☐ C. after (A) and (B) above, but before final rejection or allowance, and Applicants have made the necessary statement in box "i" below or paid the necessary fee in box "ii" below.

(check one of the boxes "i" and "ii" below:)

- ☐ i. Counsel states that, upon information and belief, each item of information listed herein was (check one of boxes (a) or (b))
- ☐ (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- ☐ (b) not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.
- ☐ ii. A check for the fee set forth in 1. 17(p), presently believed to be \$180, is enclosed.
- ☐ D. after (A), (B) and (C) above, but before payment of the issue fee: Applicant petitions under 37 C.F.R. 1.97(d) for the consideration of this IDS. Under 37 CFR 1.17(i) a check in the amount of \$180.00 is enclosed. Counsel certifies that, upon information and belief, each item of information listed herein was

(check one of the boxes "a" and "b" below:)

- ☐ (a) first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- ☐ (b) was not cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of undersigned after making reasonable inquiry, was not known to any individual designated in 1.56(c) more than three months prior to the filing of this IDS.

2. In accordance with 37 C.F.R. 1.98, this IDS includes a list (e.g., form PTO/SB/08) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. A copy of each document listed is attached, except as explained below.

(check boxes A, B and/or C and fill in blanks, if appropriate.)

- ☒ A. Pursuant to the Notice issued by the United States Patent and Trademark Office dated July 11, 2003 waiving the requirements of 37 C.F.R. § 1.98(a)(2)(i), a copy/copies of the United States Patent on PTO/SB08 is/are not being submitted.
- ☐ B. Document(s) \_\_\_\_\_ is (are) deemed substantially cumulative to document(s) \_\_\_\_\_, and, in accordance with 1.98(c), only a copy of each of the latter documents is enclosed.
- ☐ C. Certain documents were previously cited by or submitted to the Office in the following prior applications, which are relied upon under 35 U.S.C. 120:

<<INSERT SERIAL NO. & FILING DATE>>

Applicant identifies these documents by attaching hereto copies of the forms PTO-892, PTO-1449 and/or PTO/SB/08 from the files of the prior application(s) or a fresh PTO/SB/08 listing these documents, and request that they be considered and made of record in accordance with 1.98(d). Per 37 CFR 1.98(d), copies of these documents need not be filed in this application.

- ☒ 3. Cite No(s). BG, CA, CD, and CG are not in the English language. In accordance with 1.98(c), Applicant states:

- ☒ An English translation of each document (or of the pertinent portions thereof), or a copy of each corresponding English-language patent or application, or English-language abstract (or claim) is enclosed.
- ☐ The requirement for a concise explanation of the relevance of any foreign language document is satisfied by the attached search report; citation of the documents cited in the search report shall not be construed as an admission that they are or are considered to be, material to patentability of the subject matter claimed herein (See MPEP §609).
- ☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ is set forth as follows: [Insert concise explanation of relevance]
- ☐ A concise explanation of the relevance of document(s) \_\_\_\_\_ can be found on page(s) \_\_\_\_\_ of the specification.
- ☐ A concise explanation of document(s) \_\_\_\_\_ can be found on the attached sheet.
- ☐ 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 in the preamble to the final rules; 1135 OG 13 at 20).
- ☐ 5. Other information being provided for the examiner's consideration follows:

[A/An International Search Report, dated April 11, 2005, which issued during the prosecution of International Application No.PCT/HR2004/000050 which corresponds to the present application.]

6. In accordance with 37 C.F.R. 1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in §1.56 (b), or that any cited document listed or attached is (or constitutes) prior art. Unless other-wise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.

Early and favorable consideration is earnestly solicited.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: October 19, 2006

Respectfully submitted,

By 

Flynn Barrison

Registration No.: 53,970

DARBY & DARBY P.C.


P.O. Box 5257

New York, New York 10150-5257

(212) 527-7700

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant



Application No. (if known): 10/595,939

Attorney Docket No.: 03818/0204416-US0

## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

*TV 834731712-US*

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

on October 19, 2006  
Date

*Lillian Garcia*  
Signature  
*LILLIAN GARCIA*

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Information Disclosure Statement (IDS) (5 pp.)  
Information Disclosure Statement (SB/08) (3 pp.)  
Postcard

*32 Refs enclosed*



PTO/SB/08A/B (09-06)

Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		Application Number	10/595,939-Conf. #9274
		Filing Date	May 19, 2006
		First Named Inventor	Mladen Mercep
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Sheet 1 of 2	Attorney Docket Number	03818/0204416-USO	


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-6,511,976	01-28-2003	Andres-Gil et al.	
	AB*	US-4,145,434	03-20-1979	VAN DER Burg et al.	
	AC*	US-3,711,489	01-16-1973	Lombardino	
	AD*	US-4,198,421	04-15-1980	Cherkofsky et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	MM-DD-YYYY			
	BA	WO-99/19317	04-22-1999	Janssen Pharmaceutica N.V.		
	BB	WO-97/38991	10-23-1997	Janssen Pharmaceutica N.V.		
	BC	EP-0063525	10-27-1982	Centre National de la Recherche Scientifique		
	BD	WO-96/14320	05-17-1996	Janssen Pharmaceutica N.V.		
	BE	WO-96/14321	05-17-1996	Janssen Pharmaceutica Nv et al.		
	BF	CA-967,573	05-13-1975	Pfizer Inc.		
	BG	FR-2,504,140	10-22-1982	Centre Nat Rech Scient		
	BH	WO-01/87890	11-22-2001	Pliva Farmaceutska Ind Dioniko et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Gansser C. et al., "Determination of the radioprotective activity of certain analogs of imipramine" Ann. Pharmaceutiques Francaises. 1983, vol 41: pages 465-471	
	CB	Olivera R. et al., "Dibenzoxepino [4,5-d]pyrazoles: a facile approach via the Ullmann-ether reaction" Tetrahedron Letters, 2000, vol. 41: 4353-4356, 4357-4360	
	CC	Kawashiha K., et al., "Synthesis of Dibenzo [b,f] azepine Derivatives. III. Introduction of a Cyclopropane Ring by Therman Decomposition of a Pyrazoline" TakedaKenkyusho Ho., 1978, vol. 37: pages 6-11.	
	CD	Fichou D. et al., "Regioselectivite De La Cycloaddition Dipolaire--1,3" Tetrahedron, 1984, vol. 40: , No. 24, pp. 5121-5133	
	CE	Menozzi G., et al., "ω-Dialkylaminoalkyl Ethers of Phenyl-(5-substitued 1-phenyl-1H- pyrazol-4-yl)mentanols with Analgesic and Anti-inflammatory Activity" J. Heterocyclic Chem., 1997, Vol.34: Pages:963-968	
	CF	Talley J. J. et al., " 4-[5-Methy1-3-phenylisoxazol-4-yl]-benzenesulfonamide, Valdecobix: A Potent and Selective Inhibitor of COX-2", Journal of Medicinal Chemistry, , 2000, vol. 43:, No.	
Examiner Signature	/Noble Jarrell/ (09/18/2008)		Date Considered

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./ (09/18/2008)



PTO/SB/08A/B (09-08)

Approved for use through 03/31/2007. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				Application Number	10/595,939-Conf. #9274
				Filing Date	May 19, 2006
				First Named Inventor	Mladen Mercep
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	2	of	2	Attorney Docket Number	03818/0204416-US0

		5 pgs. 775-777	
CG	Jilek, J.O. et al., "Neurotrope und psychotrope Substanzen, 5 Mitt." Mh. Chem. vol. 98 (1965) pgs. 182-207		
CH	I. Ueda et al. "The Synthesis of 10-(4-Methylpiperazino)Dibenzo[b,f] thiepin and Related Compounds. 1) Neurotropic and Psychotropic Agents", Chem. Pharm. Bull. 23 (10) 2223-2231 (1975)		
CI	Saucier, C. et al. "Identification of an Endogenous 5-Hydroxytryptamine 2A Receptor in NIH-3T3 Cells: Agonist-Induced Down-Regulation Involves Decreases in Receptor RNA and Number" Journal of Neurochemistry, 1997, vol 68:, No. 1, pages 1998 - 2011		
CJ	Wolf, W.A. et al. "The Serotonin 5-HT 2C Receptor Is a Prominent Serotonin Receptor in Basal Ganglia: Evidence from Functional Studies on Serotonin-Mediated Phosphoinositide Hydrolysis" Journal of Neurochemistry, 1997, vol. 69: pgs. 1449		
CK	Thomson W. et al. " Juvenile Idiopathic Arthritis Genetics - What's new? What's next? Arthritis Research, 2002, vol 4 and 5: pgs 302-306		
CL	Millan, M.J. et al. "S18126 ((2-4-2,3-dihydrobenzo[1,4] dioxin-6-yl)piperazin-1-ylmethyl)), A Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An In vitro and In Vitro and In Vivo Comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and Raclopride, 1998, Journal of Pharmacology and Experimental Therapeutics, vol 287: No. 1 pages 167-186.		
CM	T.F. Meert, et al. " Psychopharmacology of Ritanerlin: Comparison with Chlordiazepoxide", Drug Development Research , 1989, vol. 18, pgs.119-144		
CN	F.Bymaster, et al. , " New Approaches to developing antidepressants by enhancing monoaminergic neurotransmission" Expert Opinion Investig. Drugs 2003, 12, 531-543		
CO	U. Spampinato, et al. " Role of Striatal Serotonin 2A and Serotonin 2C Receptor Subtypes in the Control of In Vivo Dopamine Outflow in the Rat Striatum" J. Neurochemistry 2000, vol. 74, pgs. 693-701		
CP	F.P. Monnet, et al. "N-Methyl-D-aspartate-induced neuronal activation is selectively modulated by $\alpha$ receptors", European Journal of Pharmacology ,1990, vol. 179,, pgs. 441-445.		
CQ	J. Ignacio Andres et al. " R107500.A new 5-HT 2A/2C Antagonist with Potential Anxiolytic Profile" Drugs Fut. 2002, vol. 27, Suppl. A: C41		
CR	Sperling, W. et al. " New Tetracyclic Antidepressants" Drugs Today , 1997, vol. 33, No. 2, pgs. 95-102.		
CS	Jose M. Cid, et al., " Synthesis of 2-aminomethyl-3, 3a, 8, 12, "Drugs Fut. 2002, vol 27, Suppl. A: P182		
CT	PCT International Search Report for International Application No. PCT/HR2004/000050, Dated April 11, 2005.		
CU	Niemegeers, C.J.E., et al. "Interaction of Drugs with Apomorphine, Tryptamine and Norepinephrine. A New 'in vivo' Approach: the ATN-Test in Rats", Arch. Int. Pharmacodyn. Vol. 227, pages 238-253 (1977).		
CV	Berge S. M. et al. "Pharmaceutical Salts," Journal of Pharmaceutical Sciences., 1977; Vol. 66: pages 1-20		
CW	Bonhaus D.W. , et al. , " The pharmacology and distribution of human 5-hydroxytryptamine2B (5HT2B) receptor gene products: comparison with 5-HT2A and 5HT2C receptors" British Journal of Pharmacology, ( 1995), Vol, 115: pages 622-628		
CX	Porsolt R.D. et al. " Behavioural Despair in Mice: A Primary Screening Test for Antidepressants" Arch. Int. Pharmacodyn. Vol. 229, pages 327-336 (1977)		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

Examiner Signature	/Noble Jarrell/ (09/18/2008)	Date Considered	
--------------------	------------------------------	-----------------	--

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /N.J./ (09/18/2008)